Project Details
| Status | Active |
|---|---|
| Effective start/end date | 09/8/25 → 03/2/27 |
Funding
- COUR Pharmaceutical Development Company Incorporated: $20,368.00
CNP-103-CL-201: A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 with Recent Onset Stage 3 Type 1 Diabetes
- Mastrandrea, Lucy (PI)
Project: Research